Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 719

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 719
---
 be used by NLS pursuant to its license agreement with Aexon Labs, Inc. Using the “Alpha -Synuclein( α -synuclein) A53T Parkinson’s Disease Genetic Cell -BasedAgonist Neurite Outgrowth Assay” by Eurofins, various DOXA compounds demonstrated positive effects on neurite outgrowth, a critical parameter of neuronal health and regeneration. Neurite outgrowth, a critical parameter of neuronal health, was measured using high -contentimaging systems to determine the efficacy of AEX compounds. Reducing α -synucleinaggregation or promoting its clearance can alleviate its toxic effects on neurons. The effects of AEX compounds on neurite outgrowth as well as their impact on Cathepsin D (CTSD) and Orexin 1 Receptor (OX1R) activities provide insights into their potential to modulate the impact of α -synuclein. Key findings • AEX -23: Its pronounced action as an OX1R agonist combined with positive effects on neurite outgrowth at specific concentrations suggests that it may modulate neuronal health through pathways influencing α -synucleindynamics, making it a potential therapeutic candidate to improve neuronal connectivity and resilience in PD. • AEX -19: Its effects at low concentrations on neurite growth coupled with OX1R agonist activity and a moderate increase in CTSD activity suggest potential neuroprotective benefits in PD. • AEX -24: The increase in CTSD activity and agonist activity on OX1R suggests the potential to enhance α -synucleindegradation, highlighting its promising therapeutic impact on PD.

| Moore Financial Consulting |

Annex E-40

AEX -23and AEX -19, which target OX1R, show promise in modulating the effects of α -synucleinon neurons, offering potential benefits in treating synucleinopathies like PD. AEX -19and AEX -24also present intriguing possibilities due to their effects on CTSD activity, suggesting pathways for reducing α -synucleinaggregation. Further in vitroresearch and in vivopreclinical studies are necessary to elucidate the precise mechanisms, optimize dosing, and evaluate the long -termefficacy and safety of these compounds in preclinical and clinical settings. NLS Therapeutics financials: Following are the Company’s Balance sheets as of December 31, 2023, and 2022 and the Proforma Balance as of June 2024:

|